Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution
Diagnosing Li-Fraumeni syndrome soon after a patient's first cancer can reduce their overall cancer burden with an improved, personalized plan. Faster identification
Collaboration or Partnership?
I had the opportunity to attend two conferences last month. The first brought me to Lugano, Switzerland, for the ESMO Sarcoma &
Key Points for Individuals with a Variant of Uncertain Significance (VUS) in the TP53 Gene
Genetic testing is not always a one and done process: the classification of a variant may change over time, technologies improve and
Li-Fraumeni Syndrome Family Education Day at Children’s National
Families of children with Li-Fraumeni syndrome are invited to join a dedicated day of education, connection, and support at Children’s
Katherine M. Howley Endowment Fund for LFS Research
The Li-Fraumeni Syndrome Association (LFSA) is honored to announce the establishment of the Katherine M. Howley Endowment Fund for
LFSA at the SU2C Summit: Progress Through Partnership
As I reflect on my recent trip to California to attend the Stand Up To Cancer Scientific (SU2C) Summit,
Lakita Frida – the Face of Resilience
Lakita Frida was an energetic dynamo when she attended her first LFSA Youth Workshop in New York City back in
Ovarian cancers have been documented in LFS patients as early as the 1980s
September is Ovarian Cancer Awareness Month! Although not originally recognized as a common “core” cancer in Li-Fraumeni syndrome (LFS), ovarian cancers were documented
Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution
Diagnosing Li-Fraumeni syndrome soon after a patient's first cancer can reduce their overall cancer burden with an improved,
Collaboration or Partnership?
I had the opportunity to attend two conferences last month. The first brought me to Lugano, Switzerland, for
Key Points for Individuals with a Variant of Uncertain Significance (VUS) in the TP53 Gene
Genetic testing is not always a one and done process: the classification of a variant may change over
Optimizing whole-body MRI for early cancer detection in Li-Fraumeni syndrome
New prospective data from a German study indicate that annual whole-body MRI for LFS surveillance could be shortened and may not require contrast agent
LFSA – Africa! “Rare genetic disorder that helps cancer run in families”
Lakita at the LFSA's Youth Workshop in 2023 LFSA - Africa's Media Relations Specialist Joel Magu has published another article in Kenyan news
Facing Sarcoma: Science, Loss, & the Power of Advocacy Podcast
Hosted by Upstate Medical University during Sarcoma Awareness Month, LFSA’s Kathy Higgins, Director of Education and Awareness, sat down with orthopedic oncologist and clinician-scientist
p53 Prophylactic Therapy for Cancer Prevention
Researchers in Singapore, Professor Kanaga Sagapathy and Christian Krueger, have published research demonstrating that introducing a third copy of the Trp53 gene in mice delays
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to cancer predisposition, as
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR), as published in
